Report
MaaT Pharma Maximising the Microbiome Monopoly
MaaT announced a business update, shedding new light on its future clinical development plans. With the exception of the remaining FDA clinical hold for MaaT013's Phase III trial, the company delivers solid progress and strong clinical results. Furthermore, the company is set to enter the CNS space as it positions MaaT033 into ALS. We issue a company note to provide our views on the case, and improve our TP from € 11 to € 12 (Accumulate rating maintained).
Underlying
MAAT PHARMA SA
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Thomas Vranken
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.